April 4th, 2017
14th Medical Innovations Summit
FOR IMMEDIATE RELEASE
PARIS, France, and CAMBRIDGE, MA, US—April 4, 2017— Lysogene (FR0013233475 – LYS), a
leading clinical-stage biopharmaceutical company specializing in innovative gene therapy technology applied to central nervous system diseases, announced today that Karen Aiach, Founder and Chief Executive Officer, will present together with Dr. Michel Zerah, Professor of Neurosurgery at Necker Enfants Malades in Paris, progress in Lysogene’s gene therapy developments for MPS IIIA and GM1 Gangliosidosis, at the Royal Society of Medicine (RSM) 14th Medical Innovations Summit in London on Saturday, April 22nd, 2017.
The following are specific details regarding Lysogene’s presentation:
Event: The Royal Society of Medicine’s 14th Medical Innovations Summit
Date: April 22, 2017
Time: 10:50 am GMT – 12:40 pm GMT, Session 2
Location: Guy-Whittle Auditorium at the Royal Society of Medicine, 1 Wimpole Street, London W1G 0AE
The summit will be attended by RSM members across 56 medical specialties. Presentations will be available for viewing online after the event on the RSM videos page. For more information and a full line-up of speakers, visit: https://www.rsm.ac.uk/medical-innovations/future- summit.aspx.
Learn more about The Royal Society of Medicine www.rsm.ac.uk
Lysogene is a leading, clinical stage biotechnology company, specializing in the basic research and clinical development of AAV gene therapy for CNS disorders with a high unmet medical need. Since 2009, Lysogene has established a solid platform and network, with lead products in Mucopolysaccharidosis Type IIIA and GM1 Gangliosidosis, to become a global leader in orphan CNS diseases. Lysogene has also obtained ODD by the EMA and FDA and rare pediatric designation by the FDA for both its MPS IIIA and GM1 programs.
Lysogene is listed on the Euronext regulated market in Paris (ISIN code: FR0013233475) For more information, please visit www.lysogene.com.
|Annie-Florence Loyer||Chris Maggos|
|+ 33 6 88 20 35 59||+41 79 367 6254|
|+ 33 1 44 71 00 12|
|+ 1 (212) 223-4017|